Advertisement
YOU ARE HERE: LAT HomeCollectionsPfizer Inc
IN THE NEWS

Pfizer Inc

FEATURED ARTICLES
BUSINESS
October 13, 1999 | DAVAN MAHARAJ, TIMES STAFF WRITER
In the nation's largest-ever trademark infringement award, a Los Angeles jury Tuesday ordered pharmaceutical giant Pfizer Inc. to pay a British company $143 million for stealing the Trovan name to market its controversial antibiotic. Legal experts called the verdict "staggering," saying it raises the stakes for companies that deliberately infringe other companies' trademarks. Jurors said Pfizer, the second-largest U.S.
ARTICLES BY DATE
BUSINESS
May 6, 2013 | By Chad Terhune
Pfizer Inc. will begin selling its popular erectile dysfunction pill Viagra to patients on its website, in an unusual move to combat counterfeit drugs. It's a novel strategy because drug-makers rarely sell medicines directly to patients, but analysts say rivals will be watching the experiment closely. Men will still need a prescription to get the little blue pills delivered to their home, but they won't have to deal with a pharmacist in the store. Online pharmacies have proliferated in recent years, hawking fake versions of Viagra and other brand-name drugs at ultra-low prices and with no prescription needed.
Advertisement
BUSINESS
December 12, 1998 | Associated Press
Hoping to improve sales of its Viagra drug, Pfizer Inc. has hired former presidential contender Bob Dole for a television advertising campaign to raise awareness about impotence. Dole, a former Senate majority leader, will participate in a series of public service activities, including speaking engagements and educational advertising that focus on impotence and men's health in general, the company said.
BUSINESS
May 1, 2013 | By Walter Hamilton, Tiffany Hsu and Andrea Chang, Los Angeles Times
First came the frenzy for iPhones and iPads. Now there's a scramble for iBonds. Apple Inc. sold $17 billion in bonds Tuesday, a gargantuan deal that ranked as the largest in global corporate history. And even though the securities are paying microscopically low interest, investors tripped over themselves to buy in. In the financial equivalent of a line stretching around the block, investors reportedly submitted more than $50 billion in requests, or more than three times the amount available.
WORLD
May 30, 2007 | From Times Wire Reports
Officials in Nigeria have brought criminal charges against pharmaceutical giant Pfizer Inc. in connection with the deaths of children who received an unapproved drug for meningitis. Authorities in Kano, the country's largest state, filed eight charges this month related to the 1996 clinical trial, including criminal conspiracy and voluntarily causing grievous harm. They also filed a suit seeking more than $2 billion in damages and restitution from Pfizer.
BUSINESS
November 3, 2004
Pfizer Inc., the world's biggest drug maker, said it bought a research center in La Jolla for $372 million in cash, gaining control of a site it had leased in the biotechnology hub.
NATIONAL
November 21, 2007 | From Times Wire Reports
Government scientists are investigating whether a prescription drug by Pfizer Inc. used to help smokers quit cigarettes also increases suicidal thoughts and violent behavior. The Food and Drug Administration said it had received reports of mood disorders and erratic behavior among patients taking Chantix. The FDA advised doctors to closely monitor patients taking Chantix for behavior changes.
BUSINESS
April 14, 1993 | Bloomberg Business News
Pfizer Inc. and Procter & Gamble Co. have scrapped plans to co-develop an osteoporosis drug after failing to agree on final commercial terms. Last September, the companies agreed to jointly develop Procter & Gamble's prescription drug, Risedronate, to treat osteoporosis. The companies said late Tuesday they were unable to reach final commercial terms, but didn't elaborate.
BUSINESS
June 27, 2003 | From Reuters
Pfizer Inc. said its experimental combination therapy for malaria was about three times as effective as the most commonly used drug for the deadly parasitic disease. The treatment combined the standard therapy, chloroquine, with Pfizer's antibiotic Zithromax. Pfizer said it would test the combination treatment in larger, late-stage clinical trials.
BUSINESS
March 29, 2013 | By Tiffany Hsu, Los Angeles Times
Just like its popular Duncan Hines cake mixes, packaged foods company Pinnacle Foods Inc. is on the rise after raising $580 million in an initial public offering. The company - which owns popular brands such as Birds Eye, Aunt Jemima, Log Cabin, Mrs. Butterworth's and Hungry-Man - made its debut on the New York Stock Exchange under the symbol PF. Wednesday night, the Parsippany, N.J., business sold 29 million shares for $20 apiece - at the top end of its suggested $18-to-$20 range.
BUSINESS
October 22, 2008 | Times Wire Reports
Pfizer Inc., the world's biggest drug maker, said profit tripled as lower costs from job cuts and higher international sales offset declining U.S. demand for its cholesterol pill Lipitor and anti-smoking drug Chantix. Sales in the U.S. fell 15% after patients continued to switch from Lipitor, the world's best-selling drug, to generic copies of Merck & Co.'s cholesterol pill Zocor, New York-based Pfizer said. Doctors also shunned Chantix after U.S. regulators cautioned it might be linked to suicides.
BUSINESS
October 1, 2008 | From the Associated Press
Pfizer Inc. is shifting its drug research focus to diseases that have high potential for big profits and for treatment improvements in such fields as cancer and Alzheimer's disease. The world's biggest drug maker also is ending new research on conditions including obesity and heart disease, but research on drugs already in late-stage human testing will continue, spokeswoman Liz Power said Tuesday.
BUSINESS
December 26, 2007 | From Times Wire Services
A judge in Nigeria ordered the arrest of three executives of New York-based drug company Pfizer Inc., saying they failed to honor an order to appear in court over a $2-billion suit the company is facing for a 1996 drug trial. Judge Shehu Atiku, sitting in Kano, Nigeria, said the executives of the Pfizer subsidiary in Nigeria had not heeded a Nov. 6 ruling that they should appear in court.
BUSINESS
November 21, 2007 | From the Associated Press
Hundreds of patients who allege they or their loved ones suffered heart attacks and strokes after taking pain medication Celebrex might be dropped from a massive lawsuit against drug maker Pfizer Inc. in light of a federal judge's ruling. U.S. District Judge Charles R.
NATIONAL
November 21, 2007 | From Times Wire Reports
Government scientists are investigating whether a prescription drug by Pfizer Inc. used to help smokers quit cigarettes also increases suicidal thoughts and violent behavior. The Food and Drug Administration said it had received reports of mood disorders and erratic behavior among patients taking Chantix. The FDA advised doctors to closely monitor patients taking Chantix for behavior changes.
BUSINESS
November 10, 2005 | From Bloomberg News
Pfizer Inc. said the Justice Department was investigating a former contractual relationship between Pharmacia Corp., which the company acquired in April 2003, and a "healthcare intermediary." The department also asked for documents and information on certain physician payments related to prescription drugs, Pfizer said in a regulatory filing.
BUSINESS
January 6, 2004 | From Bloomberg News
Pfizer Inc. may have to defend a patent for its Celebrex painkiller after a challenge by a generic-medicine maker. An unidentified company is challenging a patent on versions of Celebrex through a Food and Drug Administration application, the agency said. Celebrex, the world's top-selling arthritis drug, had sales of $701 million in the third quarter. Shares of New York-based Pfizer rose 95 cents to $36.50 on the NYSE.
BUSINESS
November 14, 2007 | From Times Wire Services
Shares of Nektar Therapeutics rose after Pfizer Inc. agreed to pay $135 million for the Exubera inhaled-insulin treatment and said it would help Nektar sell the therapy for at least two more months. Pfizer said Oct. 18 that it would stop selling the drug and return the rights back to Nektar. Pfizer, based in New York, said in a regulatory filing it would help San Carlos, Calif.-based Nektar find a new partner for the drug. Nektar gained 32 cents, or 5.5%, to $6.12.
BUSINESS
October 2, 2007 | From Times Wire Services
The Supreme Court turned down an appeal by Pfizer Inc. aimed at preventing the sale of a generic version of Norvasc, its bestselling drug for high blood pressure. The New York-based pharmaceutical firm had asked the court to overturn an appeals court ruling this year that its patent was invalid. The case began when Apotex, based in Winnipeg, Canada, challenged Pfizer's patent in 2003, requesting that regulators allow it to sell a generic version of the drug.
Los Angeles Times Articles
|